NASDAQ:SEEL

Seelos Therapeutics (SEEL) Stock Forecast, Price & News

$0.92

0.00 (0.00%)

(As of 06/9/2023 ET)

Compare

Today's Range: $0.87
▼
$0.94
50-Day Range: $0.66
▼
$1.06
52-Week Range: $0.58
▼
$1.52

Volume: 512,831 shs
Average Volume: 471,492 shs
Market Capitalization: $111.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.33

About Seelos Therapeutics (NASDAQ:SEEL) Stock

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

Receive SEEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SEEL Stock News Headlines

May 22, 2023 | finance.yahoo.com

Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences

May 21, 2023 | americanbankingnews.com

FY2023 EPS Estimates for Seelos Therapeutics, Inc. (NASDAQ:SEEL) Decreased by Cantor Fitzgerald

June 10, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

May 17, 2023 | americanbankingnews.com

Seelos Therapeutics (NASDAQ:SEEL) Price Target Cut to $4.00

May 16, 2023 | msn.com

BTIG Maintains Seelos Therapeutics (SEEL) Buy Recommendation

May 16, 2023 | msn.com

Seelos Therapeutics Positive Q1 Financials Make For 'The Most Important Year' In Company's History

May 16, 2023 | msn.com

Cantor Fitzgerald Maintains Seelos Therapeutics (SEEL) Overweight Recommendation

May 16, 2023 | americanbankingnews.com

Seelos Therapeutics (NASDAQ:SEEL) Price Target Cut to $2.00 by Analysts at Cantor Fitzgerald

June 10, 2023 | Vector Vest (Ad)

Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

May 15, 2023 | finanznachrichten.de

Seelos Therapeutics, Inc.: Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results

May 15, 2023 | markets.businessinsider.com

Seelos Therapeutics, Inc Q1 Loss decreases, but misses estimates

May 15, 2023 | msn.com

Seelos Therapeutics GAAP EPS of -$0.12 misses by $0.02, revenue of $0.81M

May 15, 2023 | markets.businessinsider.com

BTIG Reaffirms Their Buy Rating on Seelos Therapeutics (SEEL)

May 15, 2023 | finance.yahoo.com

Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results

May 13, 2023 | marketwatch.com

2030, Psychedelic Drugs Market: Trend & Outlook

May 5, 2023 | finance.yahoo.com

Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

April 14, 2023 | msn.com

ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today

April 6, 2023 | msn.com

Unusual Call Option Trade in Seelos Therapeutics (SEEL) Worth $17.57K

April 4, 2023 | finance.yahoo.com

Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program

March 31, 2023 | markets.businessinsider.com

BTIG Remains a Buy on Seelos Therapeutics (SEEL)

March 30, 2023 | marketwatch.com

Psychedelic Medicine Market research Report with Analysis 2023 To 2030

March 30, 2023 | marketwatch.com

Psychedelic Drugs Market Analysis, Industry Report, Trends 2029

March 29, 2023 | finance.yahoo.com

Seelos Therapeutics Announces Business Update on its Key Programs

March 25, 2023 | americanbankingnews.com

Seelos Therapeutics (NASDAQ:SEEL) Price Target Lowered to $4.00 at Benchmark

March 14, 2023 | msn.com

Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today

March 10, 2023 | marketwatch.com

Seelos Therapeutics Prices Direct Offering With Proceeds of $11.2M

March 10, 2023 | finance.yahoo.com

Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock

See More Headlines

SEEL Price History

30 days | 90 days | 365 days | Advanced Chart

SEEL Company Calendar

Last Earnings: 5/15/2023
Today: 6/09/2023
Next Earnings (Estimated): 8/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SEEL
CUSIP: N/A
CIK: 1017491
Web: www.seelostherapeutics.com
Phone: (646) 293-2100
Fax: 858-436-8155
Employees: 15
Year Founded: 2016

Price Target and Rating

Average Stock Price Forecast: $3.33
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +264.3%
Consensus Rating: N/A
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-73,530,000.00
Net Margins: N/A
Pretax Margin: -9,030.20%
Return on Equity: -10,287.49%
Return on Assets: -209.12%

Debt

Debt-to-Equity Ratio: 1.36
Current Ratio: 0.60
Quick Ratio: 0.60

Sales & Book Value

Annual Sales: $808,000.00
Price / Sales: 137.94
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.10) per share
Price / Book: -9.15

Miscellaneous

Outstanding Shares: 121,811,000
Free Float: 114,015,000
Market Cap: $111.46 million
Optionable: Not Optionable
Beta: 1.73

Social Links

Key Executives

Raj Mehra
Chairman, President & Chief Executive Officer

Michael Golembiewski
Chief Financial Officer

Timothy J. Whitaker
Chief Medical Officer

Gopal Krishna
Head-Manufacturing & Technical Operations

Karen Fusaro
Senior Vice President & Head-Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SEEL Stock - Frequently Asked Questions

What is Seelos Therapeutics' stock price forecast for 2023?: 0 Wall Street research analysts have issued twelve-month price targets for Seelos Therapeutics' stock. Their SEEL share price forecasts range from $2.00 to $4.00. On average, they expect the company's share price to reach $3.33 in the next year. This suggests a possible upside of 264.3% from the stock's current price.
View analysts price targets for SEEL or view top-rated stocks among Wall Street analysts.
How have SEEL shares performed in 2023?: Seelos Therapeutics' stock was trading at $0.6790 at the start of the year. Since then, SEEL shares have increased by 34.8% and is now trading at $0.9150.
View the best growth stocks for 2023 here.
When is Seelos Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our SEEL earnings forecast.
How were Seelos Therapeutics' earnings last quarter?: Seelos Therapeutics, Inc. (NASDAQ:SEEL) released its quarterly earnings data on Monday, May, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter. The firm had revenue of $0.81 million for the quarter.
What ETF holds Seelos Therapeutics' stock ?: AdvisorShares Psychedelics ETF holds 399,133 shares of SEEL stock, representing 5.54% of its portfolio.
What other stocks do shareholders of Seelos Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK).

What is Seelos Therapeutics' stock symbol?: Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."
Who are Seelos Therapeutics' major shareholders?: Seelos Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Gendell Jeffrey L (4.16%), BlackRock Inc. (1.36%), Mirae Asset Global Investments Co. Ltd. (1.18%), Geode Capital Management LLC (0.93%), Uniplan Investment Counsel Inc. (0.93%) and Wealth Effects LLC (0.78%). Insiders that own company stock include Daniel J O'connor and Raj Mehra.
View institutional ownership trends.
How do I buy shares of Seelos Therapeutics?: Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Seelos Therapeutics' stock price today?: One share of SEEL stock can currently be purchased for approximately $0.92.
How much money does Seelos Therapeutics make?: Seelos Therapeutics (NASDAQ:SEEL) has a market capitalization of $111.46 million and generates $808,000.00 in revenue each year.
How can I contact Seelos Therapeutics?: Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The official website for the company is www.seelostherapeutics.com. The company can be reached via phone at (646) 293-2100, via email at anthony.marciano@seelostx.com, or via fax at 858-436-8155.

This page (NASDAQ:SEEL) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Seelos Therapeutics (SEEL) Stock Forecast, Price & News

About Seelos Therapeutics (NASDAQ:SEEL) Stock

SEEL Stock News Headlines

SEEL Price History

SEEL Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

SEEL Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info